Emergent BioSolutions (EBS) Stock Price
Emergent BioSolutions Price
Over the last 19 years Emergent BioSolutions grew revenue by 8.7% annually, reaching 742.90 M USD. Earnings per share have grown at 1.7% per year over the last 19 years. For Emergent BioSolutions, the net margin of 7.1% is down versus 12.4% a few years ago. The consensus 12-month price target for Emergent BioSolutions is 10.00 USD, about 46.4% above where the stock trades today. Of 7 analysts, 5 rate the stock a buy — an overall Buy consensus.
Emergent BioSolutions stock price
Emergent BioSolutions business model & stock analysis
Frequently asked questions about Emergent BioSolutions
The business model of Emergent BioSolutions Inc revolves around being a global specialty biopharmaceutical company. With a focus on developing and manufacturing vaccines and therapeutics, Emergent BioSolutions Inc aims to address public health threats. The company operates through three segments: Vaccines and Anti-Infectives, Contract Development and Manufacturing Organization (CDMO), and Devices. Through partnerships, strategic acquisitions, and government contracts, Emergent BioSolutions Inc has built a strong portfolio of products and capabilities to provide solutions in areas such as infectious diseases, opioid overdose, and weapons of mass destruction.
Emergent BioSolutions Inc is primarily active in the biopharmaceutical industry.
Emergent BioSolutions Inc faces competition from several players in the market. Some of the main competitors of Emergent BioSolutions Inc include companies like Pfizer Inc, GlaxoSmithKline plc, Sanofi SA, and Johnson & Johnson. These companies are also involved in the biopharmaceutical sector and operate in similar areas such as vaccine development, contract manufacturing, and biodefense solutions. However, Emergent BioSolutions Inc has positioned itself as a leader in the industry, particularly due to its expertise in biodefense solutions and its strong portfolio of products and services.
Emergent BioSolutions Inc is a renowned pharmaceutical company with a rich history and background. Established in 1998, Emergent is dedicated to developing innovative solutions to address public health threats. Over the years, the company has built a strong reputation for its expertise in biodefense, vaccines, therapeutics, and contract manufacturing services. Emergent BioSolutions has played a crucial role in supplying vaccines and treatments for various diseases, including anthrax, smallpox, and COVID-19. With a commitment to protecting and enhancing global health, Emergent continues to be at the forefront of life-saving medical advancements.
Emergent BioSolutions Inc, a leading biopharmaceutical company, has achieved significant milestones in its journey. Notably, the company received a U.S. FDA licensure for its proprietary BioThrax® vaccine against anthrax, establishing itself as the sole provider of such a critical defense product for the U.S. government. Additionally, Emergent successfully developed and commercialized various medical countermeasures, including Vaccinia Immune Globulin Intravenous (VIGIV) for smallpox treatment and Trobigard® auto-injector for atropine/pralidoxime chloride poisoning. Furthermore, the company obtained FDA approval for its first-in-class narcolepsy therapy, NARCAN® nasal spray. These achievements highlight Emergent BioSolutions Inc's commitment to enhancing public health through innovative solutions and its contributions to epidemic and pandemic preparedness.
Emergent BioSolutions Inc primarily operates in the United States. As a global specialty biopharmaceutical company, the company's headquarters are located in Gaithersburg, Maryland. With a strong presence in the United States, Emergent BioSolutions Inc focuses on developing and manufacturing therapies for public health threats. The company's products are used in various countries and regions worldwide, supporting preparedness and response efforts for biodefense, emerging infectious diseases, and other public health emergencies.
Emergent BioSolutions Inc represents values of integrity, innovation, and dedication to public health. Following their corporate philosophy, they strive to deliver high-quality products and solutions for public health threats. The company focuses on developing, manufacturing, and delivering medical countermeasures for biodefense and emerging infectious diseases. By collaborating with governments, healthcare organizations, and stakeholders worldwide, Emergent BioSolutions Inc aims to protect and enhance the well-being of individuals and communities. With a commitment to scientific expertise and a patient-centered approach, they contribute to the preparedness and response efforts in the face of various health challenges.
Analysts currently set an average price target of 10.00 USD for the Emergent BioSolutions stock (median: 10.00 USD), implying +46.4 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Emergent BioSolutions stock: 5 recommend buying, 1 holding and 1 selling. For 2026, analysts expect Emergent BioSolutions to generate revenue of 657.02 M USD and earnings per share of 0.36 USD.
Converted at the current exchange rate, the Emergent BioSolutions share trades at 6.09 EUR (6.83 USD).
The Emergent BioSolutions share (EBS) is listed on 7 stock exchanges, including: NYSE (EBS), London (0IGA.L), SIX (Zürich) (ER4.SW), Frankfurt (ER4.F), München (ER4.MU), Düsseldorf (ER4.DU).
Emergent BioSolutions Inc. is a US biotechnology company based in Gaithersburg, Maryland. They specialize in the development and manufacturing of biological products, including vaccines and antibodies, to combat infectious diseases, as well as medications and products for emergency situations. The company is divided into three business segments: BioDefense, Civilian Emergency Medicine, and Emergent Family of Companies. Each segment focuses on a specific market and has its own products. The BioDefense segment develops and produces vaccines and antibodies used to combat bioterrorist threats such as anthrax, smallpox, and botulism. This includes the BioThrax vaccine, the only FDA-approved anthrax vaccine in the US, as well as anthrax countermeasures such as Anthrasil. In Civilian Emergency Medicine, Emergent offers products for the treatment of acute medical emergencies, including medical devices and diagnostic equipment for rapid testing. In this segment, Emergent also has several partnerships with government agencies and health organizations to provide products needed in natural disasters and other emergencies. The Emergent Family of Companies includes Emergent's acquisitions and partnerships in other areas and niches of biotechnology, including medical device manufacturing and the development of therapies for various indications such as cancer, autoimmune diseases, and infectious diseases. An important focus of Emergent is collaboration with government agencies and international partners. The company has a specialized team that works with various government organizations and institutions in the US and around the world. This gives Emergent access to specialized resources and enables them to develop and produce products that meet the requirements of the respective government agencies and organizations. As a company with a strong focus on research and development, Emergent invests significant amounts in expanding its product pipeline. Future products include vaccines and therapies for HIV, Ebola, and Zika. Emergent primarily markets its products to government agencies and health organizations. However, the company also benefits from the increasing demand for products to combat infectious diseases due to natural disasters or bioterrorist attacks. Overall, Emergent BioSolutions is a key player in the medical and biotech industry, especially in terms of the development and production of biologics. The company's threefold division allows it to operate in various biotechnology niches and constantly expand its product pipeline. Collaboration with government agencies and the ability to quickly respond to changing requirements are crucial factors for the success of Emergent BioSolutions.
The expected revenue of Emergent BioSolutions is 657.02 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Emergent BioSolutions is 19.06 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Emergent BioSolutions is currently 18.78. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Emergent BioSolutions stock.
The price-to-sales ratio (P/S) of Emergent BioSolutions is currently 0.54. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Emergent BioSolutions stock.
The Eulerpool Quality Score for Emergent BioSolutions is 3/10.
The ISIN of Emergent BioSolutions is US29089Q1058. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Emergent BioSolutions is A0LC2W. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Emergent BioSolutions is EBS. The ticker symbol is used to trade Emergent BioSolutions shares on the stock exchange.
Emergent BioSolutions stock
Emergent BioSolutions Peer Group
Emergent BioSolutions Ticker
Emergent BioSolutions FIGI
All fundamentals and in-depth analysis of Emergent BioSolutions
Our stock analysis for Emergent BioSolutions stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Emergent BioSolutions. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.